mechanisms of the onset of hepatitis after BMT in patients with positive HCV antibody. The hepatitis C virus (HCV) infection has, in general, been considered not to affect liver function severely durCase reports ing the course of bone marrow transplantation (BMT) except for late hepatitis which coincided with a decrease Case 1 in immunosuppressive therapy. We examined serial sera of two patients with positive HCV antibody who A 32-year-old woman underwent allogeneic BMT from a underwent allogeneic BMT and found that while the sibling donor for acute myelogenous leukemia. Before dose of cyclosporin A tapered off, the serum concen-BMT, her aspartate aminotransferase (AST) and alanine tration of HCV core protein increased before the occuraminotransferase (ALT) levels were 21 and 35 IU/l, rence of hepatitis. This suggests that viral reactivation respectively, and her anti-HCV antibody test was positive. and growth might be one of the important mechanisms CsA was given intravenously until 61 days after BMT, of hepatitis after BMT in patients with positive HCV when it was changed to the oral form. Except for a transient antibody.
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The hepatitis C virus (HCV) infection has, in general, been considered not to affect liver function severely durCase reports ing the course of bone marrow transplantation (BMT) except for late hepatitis which coincided with a decrease
Case 1 in immunosuppressive therapy. We examined serial sera of two patients with positive HCV antibody who A 32-year-old woman underwent allogeneic BMT from a underwent allogeneic BMT and found that while the sibling donor for acute myelogenous leukemia. Before dose of cyclosporin A tapered off, the serum concen-BMT, her aspartate aminotransferase (AST) and alanine tration of HCV core protein increased before the occuraminotransferase (ALT) levels were 21 and 35 IU/l, rence of hepatitis. This suggests that viral reactivation respectively, and her anti-HCV antibody test was positive. and growth might be one of the important mechanisms CsA was given intravenously until 61 days after BMT, of hepatitis after BMT in patients with positive HCV when it was changed to the oral form. Except for a transient antibody.
increase in AST and ALT levels shortly after BMT, no Keywords: cyclosporin A; hepatitis C virus; bone marmarked liver dysfunction was observed until 3 months after row transplantation the dose of CsA was decreased. No other immunosuppressive therapy including corticosteroid hormone was used, nor was any other medication changed meanwhile. The last HCV-negative blood transfusion was on day 154. A liver The effects of hepatitis C virus (HCV) on patients who biopsy done during hepatitis revealed chronic active hepahave undergone bone marrow transplantation (BMT) have titis without bridging fibrosis. Hepatitis subsided sponbeen evaluated and the risk of veno-occlusive disease and taneously but neither her liver enzymes nor the concensevere liver failure have been reported to be high.
1,2 Howtration of HCV core protein ever returned to the pre-BMT ever, in other reports, HCV has been considered not to level. Seroconversion did not occur. affect liver function severely during BMT. 3, 4 Occurrence of late hepatitis, however, has been reported repeatedly and
Case 2 an immunological reactivation with a decrease in immunosuppressive therapy has been considered as the main mech-A 39-year-old female with acute myelogenous leukemia in anism of such hepatitis. 3, 5, 6 Interestingly, patients who had a second complete remission underwent allogeneic BMT seroconverted after BMT were also reported even though from an unrelated, HLA matched donor, 8 years after the there is a possibility that those patients with positive antiinitial diagnosis. Anti-HCV antibody was positive before HCV antibody might have been transfused with immuno-BMT but liver function tests were within normal ranges. globulins which contain anti-HCV antibody. 5 CsA was started orally on day 75 and no other immunosupWe examined serial sera of two patients with positive pressive therapy was used afterwards. No marked liver dys-HCV antibody who underwent allogeneic BMT and found function was observed until 2 months after the discontinuthat while the dose of cyclosporin A (CsA) tapered off, the ation of CsA. Hepatitis subsided spontaneously and other concentration of HCV core protein increased just before medications were not changed during this time. the occurrence of active hepatitis. This suggests that viral reactivation and growth might be one of the important bodies, 5E3 and 5F11, directed against the HCV core proDiscussion tein were used. HCV core protein levels correlate well with HCV RNA levels with Spearman's correlation coefficient
The mechanism by which HCV damages the liver remains of 0.817. 8 The titer of antibody against C7 (NS3) was also unclear. HCV might be cytopathic to liver cells while measured using Imucheck HCV Ab (International Reagents immune-mediated damage might be the mechanism as in Corporation, Kobe, Japan). The serum samples were stored hepatitis B virus infection. Fong et al 9 reported that ALT at −80°C. levels decreased during prednisone therapy while the level of HCV RNA increased. Both returned to pretreatment levels when the prednisone was discontinued, suggesting that Results an immune-mediated mechanism is at least partially responsible for HCV hepatitis. In the first case, the viral level increased significantly while HCV infected patients also develop hepatitis after the dose of CsA declined (Figure 1a) . A month later, liver immunosuppressive therapy. Two cases of fulminant hepafunction tests revealed hepatocellular damage. The titis after BMT related to HCV have been reported. 5 maximum HCV core protein level reached more than According to other reports, however, HCV was considered 1500 pg/ml which was equivalent to 10 8 viral particles/ml. not to affect the course of BMT except for hepatitis coincidIn the second case, the level of HCV core protein showed ing with a decrease in or discontinuation of immunosupthe same tendency as in the first case and the concentration pressive treatment. 3, 4 As the pathogenesis of this type of of HCV core protein increased while the dose of CsA hepatitis, reactivation of the immune-mediated mechanisms declined. This occurred a month before the hepatocellular has been proposed. 6 damage ( Figure 1b) . In our two patients, the HCV core protein level increased The titers of antibody against C7 are presented in while the dose of CsA was tapered off and this was before Figure 1 . In both cases, the titer declined steadily after the liver function tests showed any evidence of hepatocellu-BMT and the relationship between the titer of antibody and lar damage. Viral replication also seemed to be suppressed the core protein concentration could not be defined clearly.
while the patient was on CsA treatment in case 1. In case 2, however, the suppressive effect of CsA could not be evaluated because FK506 and prednisolone had been used initially instead of CsA.
No clear relationship was observed between the titer of antibody against C7 and the concentration of core protein in these two cases even though the titer steadily declined after BMT. Because these patients received no immunoglobulins after BMT, this seems to correlate with the declining level of serum immunoglobulins observed in patients after BMT in general.
It is suggested, therefore, that replication or excretion of HCV itself might be one of the mechanisms of hepatitis coinciding with a decrease in CsA dose. The mechanism of this phenomenon is unclear, but because CsA is known to suppress replication of HIV-1 by inhibiting cyclophilin, 
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